Replication-defective bovine adenovirus type 3 as an expression vector

Area of Science:

• * Virology
• * Gene Therapy
• * Vaccinology

Background:

• * Recombinant human adenovirus (HAV)-based vectors are used in gene therapy and vaccination.
• * There is a need for alternative vectors with improved expression duration and reduced toxicity.
• * Bovine adenovirus type 3 (BAV-3) presents a potential alternative vector system.

Purpose of the Study:

• * To develop a replication-defective BAV-3 vector for gene therapy and vaccination.
• * To create and characterize bovine cell lines that complement BAV-3 E1A deletions.
• * To evaluate the potential of BAV-3 as a vector for cattle diseases and human gene therapy.

Main Methods:

• * Construction of replication-defective BAV-3 by deleting E1A and E3 regions.
• * Development of bovine cell lines (VIDO R2 and 6.93.9) to complement BAV-3.
• * Generation of recombinant BAV-3 vectors expressing foreign genes (bovine herpesvirus type 1 glycoprotein D, bovine coronavirus hemagglutinin-esterase).

Main Results:

• * Replication-defective BAV-3 vectors were successfully generated and grown in complementing cell lines.
• * The E1A region of human adenovirus type 5 (HAV-5) can complement BAV-3 E1A deletions.
• * Recombinant BAV-3 vectors demonstrated suitability for animal studies on safety, gene expression, and immunogenicity.

Conclusions:

• * Development of E1A-complementing bovine cell lines and replication-defective BAV-3 vectors is a significant advancement.
• * BAV-3 vectors hold potential for vaccination against cattle diseases and somatic gene therapy in humans.
• * Further animal studies are warranted to fully define the safety and efficacy of BAV-3 vectors.